These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6315778)

  • 1. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition.
    Mann JJ
    J Clin Psychopharmacol; 1983 Dec; 3(6):363-6. PubMed ID: 6315778
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
    Kennedy SH
    J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory depression treated with high doses of monoamine oxidase inhibitor.
    Guze BH; Baxter LR; Rego J
    J Clin Psychiatry; 1987 Jan; 48(1):31-2. PubMed ID: 3804984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression].
    Nolen WA
    Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1940-3. PubMed ID: 14574774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase inhibitors revisited: what you should know.
    Goldberg JF; Thase ME
    J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship between the pharmacological and biochemical properties of a monoamine oxidase inhibitor preferentially affecting 5-hydroxytryptamine oxidation.
    Christmas AJ; Hall DW; Hayward A; Maxwell DR
    Br J Pharmacol; 1970 May; 39(1):207P-208P. PubMed ID: 5420104
    [No Abstract]   [Full Text] [Related]  

  • 7. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.
    Beasley CM; Masica DN; Heiligenstein JH; Wheadon DE; Zerbe RL
    J Clin Psychopharmacol; 1993 Oct; 13(5):312-20. PubMed ID: 8227489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between tranylcypromine sulfate dose and monoamine oxidase inhibition.
    Grasso RA; Perry PJ; Sherman AD
    DICP; 1991 Jan; 25(1):99-100. PubMed ID: 2008794
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of five clinically used inhibitors of monoamine oxidase using the fluorescence microscopy method.
    Bartonícek V
    Med Pharmacol Exp Int J Exp Med; 1967; 16(2):142-6. PubMed ID: 5298397
    [No Abstract]   [Full Text] [Related]  

  • 11. Do monoamine oxidase inhibitors alter carbamazepine blood levels?
    Barklage NE; Jefferson JW; Margolis D
    J Clin Psychiatry; 1992 Jul; 53(7):258. PubMed ID: 1639748
    [No Abstract]   [Full Text] [Related]  

  • 12. [High dosage tranylcypromine treatment of "therapy refractory" depressions].
    Schmauss M
    Nervenarzt; 1996 May; 67(5):390-3. PubMed ID: 9005348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study.
    Rabkin J; Quitkin F; Harrison W; Tricamo E; McGrath P
    J Clin Psychopharmacol; 1984 Oct; 4(5):270-8. PubMed ID: 6386898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors.
    Fallon B; Foote B; Walsh BT; Roose SP
    J Clin Psychiatry; 1988 Apr; 49(4):163-5. PubMed ID: 3281932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abuse of the monoamine oxidase (MAOI) inhibitors as antidepressive drugs: a critical review].
    García-Campayo JJ; Sanz-Carrillo C; Ferrández Payo M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(4):217-22. PubMed ID: 7484306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke resulting from a rapid switch from phenelzine to tranylcypromine.
    Mattes JA
    J Clin Psychiatry; 1998 Jul; 59(7):382. PubMed ID: 9714269
    [No Abstract]   [Full Text] [Related]  

  • 17. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
    Ketter TA; Post RM; Parekh PI; Worthington K
    J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase inhibitor-induced speech blockage.
    Goldstein DM; Goldberg RL
    J Clin Psychiatry; 1986 Dec; 47(12):604. PubMed ID: 3782047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    J Clin Psychiatry; 2004 Nov; 65(11):1505-10. PubMed ID: 15554763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.